

KRYSTAL-1

KRYSTAL-1 is a Phase 1/2 clinical trial investigating the selective KRAS G12C inhibitor **adagrasib (MRTX849)** in patients with advanced solid tumors.

□ General Information

- **Drug:** Adagrasib (MRTX849)
- **Trial Phase:** Phase 1/2
- **Target Mutation:** KRAS G12C
- **Tumor Types Studied:**
 - Colorectal Cancer (CRC)
 - Non-Small Cell Lung Cancer (NSCLC)
 - Other solid tumors

□ Results in Colorectal Cancer (CRC)

Adagrasib Monotherapy

- **Objective Response Rate (ORR):** 19%
- **Median Progression-Free Survival (PFS):** 5.6 months
- **Median Overall Survival (OS):** 19.8 months

Adagrasib + Cetuximab Combination

- **ORR:** 34%
- **Disease Control Rate (DCR):** 85.1%
- **Median Duration of Response:** 5.8 months
- **Median PFS:** 6.9 months
- **Median OS:** 15.9 months
- **Grade 3-4 Treatment-Related Adverse Events:** 27.7%
- **Grade 5 Events:** None reported

□ Results in Non-Small Cell Lung Cancer (NSCLC)

- **ORR:** 43%
- **Median Duration of Response:** 8.5 months
- **Median PFS:** 6.5 months
- **Median OS:** 12.6 months

Regulatory Update

- In **June 2024**, the **FDA granted accelerated approval** for the combination of adagrasib + cetuximab in patients with previously treated KRAS G12C-mutant metastatic CRC.

Sources

- [NEJM article on NSCLC arm](#)
- [PubMed: CRC data](#)
- [FDA approval notice \(2024\)](#)

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

<https://neurosurgerywiki.com/wiki/doku.php?id=krystal-1>

Last update: **2025/05/03 10:30**

